U.S. Markets closed

Global Vaccines Market to Reach $43.79 Billion by 2022 | An Exclusive Research Report By The Business Research Company

LONDON, Sept. 16, 2019 /PRNewswire/ -- The global vaccines market, valued at around $30 billion in 2018, has been witnessing multiple strategic initiatives and mergers and acquisitions in the recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. For instance, in February 2019, Bharat Biotech acquired Chiron Behring Vaccines, a clinical biotechnology company, one of the leading manufacturers of rabies vaccines across the globe. Similarly, in 2017, Takeda Pharmaceutical acquired ARIAD Pharmaceuticals for approximately $5.2 billion, and Sanofi acquired Protein Sciences for $650 million. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally.

The Business Research Company Logo

In October 2018, Emergent BioSolutions, a multinational specialty biopharmaceutical company, acquired PaxVax for $270 million. This acquisition would strengthen and expand Emergent BioSolution's product portfolio with PaxVax's typhoid vaccine Vivotif, cholera vaccine Vaxchora, and additional clinical-stage vaccine used in the prevention of typhoid fever, cholera, chikungunya and other emerging infectious diseases. PaxVax is a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. PaxVax was founded in 2006 and is headquartered in Cayman Islands, a British Overseas Territory.

Read More On The Business Research Company's Vaccines Market Report @ https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report


Place a DIRECT Purchase order of this complete research report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2556 .

Increasing Awareness On Immunization Will Drive The Global Vaccines Market

The global vaccines market is expected to grow to $43.79 billion at an annual growth rate of more than 10% through 2022. Rising awareness on immunization and vaccination benefits in emerging markets is consistently driving the global vaccines market growth. The World Health Organization (WHO) is taking initiatives to increase awareness of immunization through the global vaccine action plan (GVAP) and global Immunization vision and strategy (GIVS). They aim to strengthen routine immunization, control morbidity and mortality from vaccine preventable diseases, and help countries to immunize more people with a greater range of vaccines. The organization accomplishes this work through its biological programme, the WHO Collaborating Centers, and the WHO Expert Committee on Biological Standardization (ECBS). In 2017, according to WHO statistics, 85% of the total infants across the globe (116.2 million), received 3 doses of diphtheria-tetanus-pertussis vaccine in order to increase immunization and protect them against infectious diseases that can cause serious illness and disability. Furthermore, 123 countries reached 90% coverage of DTP3 vaccine in 2017.

Severe Shortage Of Skilled Healthcare Professionals Will Hinder The Vaccines Market Growth

The vaccines market growth is limited due to severe shortage of skilled healthcare professionals for developing biologics drugs, which requires specialized skillsets. These skillsets are limited to some research organizations and medical equipment companies in the USA and Europe. As of 2018, 40% of the biopharma industry was facing difficulties in hiring for process development staff due to shortage of talent. This shortage also led to rise in competition and salaries for the limited talent pool available for biologics talent, further limiting growth of the vaccines market.

Regulations In The Vaccines Market

The Food and Drug Administration (FDA) is the National Regulatory Authority (NRA) in the United States responsible for assuring quality, safety, and effectiveness of all vaccines for human use. The Center for Biologics Evaluation and Research (CBER) within the US FDA is responsible for regulating the vaccines market. Governments across the world are encouraging the research and development of biologics in order to develop more targeted therapies and vaccines for various diseases. In May 2014, the US's FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, and orphan drugs for rare diseases, while preserving the safety and efficacy standards. In 2016, the FDA also removed a rule (Section 610.21 of the FDA code) which specified minimal potency limits for certain antibodies and antigens. In addition, the FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. Inquire for Sample Of The Vaccines Market Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2556&type=smp .

Here Is A List Of Similar Reports By The Business Research Company:

Biologics Market By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By Trends, By Regions And By Key Players - Global Forecast To 2021

Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022

The World's Most Comprehensive Database:

The Business Research Company's Global Market Model analyzes all the above data and more. It is the world's most comprehensive database of integrated market information. This market intelligence platform covers various macroeconomic indicators and metrics across 56 geographies and 24 industries.

Interested to know more about The Business Research Company?

The Business Research Company has published over 300 industry reports, covering over 2400 market segments and 56 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact Information
The Business Research Company 
Email: info@tbrc.info
Europe: +44-207-1930-708
Asia: +91-8897263534
Americas: +1-315-623-0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_Info


View original content:http://www.prnewswire.com/news-releases/global-vaccines-market-to-reach-43-79-billion-by-2022--an-exclusive-research-report-by-the-business-research-company-300918638.html